{
    "Trade/Device Name(s)": [
        "ADVIA Centaur Herpes-1 IgG"
    ],
    "Submitter Information": "Biokit, S.A.",
    "510(k) Number": "K181333",
    "Predicate Device Reference 510(k) Number(s)": [
        "K000238"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MXJ"
    ],
    "Summary Letter Date": "May 17, 2018",
    "Summary Letter Received Date": "May 25, 2018",
    "Submission Date": "May 17, 2018",
    "Regulation Number(s)": [
        "21 CFR 866.3305"
    ],
    "Regulation Name(s)": [
        "Herpes simplex virus serological assays"
    ],
    "Analyte Class(es)": [
        "serology",
        "virology"
    ],
    "Analyte(s)": [
        "IgG antibodies to herpes simplex virus type 1 (HSV-1)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (EDTA)",
        "Plasma (lithium heparin)"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Lithium heparin tube",
        "Serum tube",
        "Serum separator tube (SST)"
    ],
    "Instrument(s)/Platform(s)": [
        "ADVIA Centaur systems",
        "ADVIA Centaur XP"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay",
        "Two-step sandwich immunoassay",
        "Indirect immunoassay"
    ],
    "Methodologies": [
        "Serological antibody detection",
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA Centaur Herpes-1 IgG automated chemiluminescent immunoassay for qualitative detection of IgG antibodies to HSV-1 in serum and plasma",
    "Indications for Use Summary": "Qualitative determination of IgG antibodies to herpes simplex virus type 1 (HSV-1) in human serum and plasma (EDTA and lithium heparin) using ADVIA Centaur systems, aiding in presumptive diagnosis of HSV infection in sexually active adults or expectant mothers",
    "fda_folder": "Microbiology"
}